AMG 102
Drug timelines are a Plus or Pro feature.
6 regulatory and trial events tracked for AMG 102, covering 2013-08-02 to 2020-11-17. Get the full timeline:
Most recent: Clinical Trial Update: MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma [Phase 2]